This list is an analysis based on recent market events. It's not an investment recommendation.
About
Ergomed plc, together with its subsidiaries, provides clinical trial planning, management, and monitoring; and drug safety and medical information services in the United Kingdom, Rest of Europe, the Middle East, Africa, North America, Asia, and Australia. It operates through two segments, Clinical Research Outsourcing and Pharmacovigilance. The company provides and manages clinical development, post-approval management, and pharmacovigilance services for pharmaceutical and generics companies, as well as small and mid-sized drug development companies. It focuses on various therapeutic areas, including oncology, haematology, allergy, respiratory, and neurology/CNS, as well as develops orphan drugs. The company also provides site support services. The company was formerly known as Ergomed Clinical Research Limited and changed its name to Ergomed plc in June 2014. Ergomed plc was founded in 1997 and is headquartered in Guildford, the United Kingdom.
Depending on the exchange, the stock ticker may vary. For instance, on Warsaw Stock Exchange exchange LUNA GLOBAL SPÓŁKA AKCYJNA stocks are traded under the ticker LGL.WA.
What is LUNA GLOBAL SPÓŁKA AKCYJNA revenue for the last year?▼
LUNA GLOBAL SPÓŁKA AKCYJNA revenue for the last year amounts to 0 PLN.
What is LUNA GLOBAL SPÓŁKA AKCYJNA net income for the last year?▼
LGL.WA net income for the last year is -996,000 PLN.
Does LUNA GLOBAL SPÓŁKA AKCYJNA pay dividends?▼
Yes, LGL.WA dividends are paid annual. The last dividend per share was 0.2 . As of today, Dividend Yield (FWD)% is 0%.
In which sector is LUNA GLOBAL SPÓŁKA AKCYJNA located?▼
LUNA GLOBAL SPÓŁKA AKCYJNA operates in the Other sector.
When did LUNA GLOBAL SPÓŁKA AKCYJNA complete a stock split?▼
LUNA GLOBAL SPÓŁKA AKCYJNA has not had any recent stock splits.